Skip to main content

Type 2 diabetes - a membrane trafficking disease?


I heard a great talk yesterday by Dr. Patrik Rorsman from the University of Oxford, who has a new way of thinking about type 2 diabetes. He believes some individuals who develop the disease may have a deficit in insulin exocytosis, but not by the mechanism that anyone would have predicted.
It is abundantly clear that type-2 diabetes is not caused by a lack of available insulin in the pancreas. Therefore, Dr. Rorsman hypothesized that the mechanism of exocytic release of insulin may be perturbed in diabetic patients. However, when he made classical measurements to detect exocytic release in primary tissues, such as amperometry of cargo release and monitoring membrane capacitance, he saw no differences between healthy and diseased cells. It wasn’t until he engineered an elegant ATP-sensitive, feedback biosensor into his recording set-up that he detected a difference in exocytosis.
What he found suggests that the equilibrium between kiss-and-run and full-fusion exocytic events is slightly perturbed in diabetic tissue, such that insulin-containing granules are a little bit less likely to fully fuse with the membrane and release all their cargo. During the kiss-and-run events, the neck of the fusing granule acts as a sieve and prevents insulin from leaking out. The overall effect of too many kiss-and-run events then is reduced insulin release and decreased glucose sensitivity.
Furthermore, he found that this subtle change in exocytic equilibrium in beta cells correlates very well with the expression of Sox4, a transcription factor identified in a screen of tissues from hundreds of patients, both diabetic and healthy. Sox4 regulates Amisyn, a syntaxin-6 binding protein that appears to compete with normal SNAREs to inhibit full granule fusion. Amycin correlated with increased resting blood glucose levels and decreased insulin release in the patient screen as well, further implying a link to its role in granule exocytosis.
Dr. Rorsman is interested now in targeting this pathway to correct the balance of exocytic events in the pancreas and restore glucose sensitivity to diabetic tissue, and he already has some therapeutic ideas. He also believes Sox4 expression is likely misregulated in a subset of diabetic individuals and we should pay attention to it as a potential biomarker for development of the disease. It will be interesting to know whether some genotypes are more susceptible to Sox4 misregulation, or if lifestyle also plays a role in its expression.




Labels:

Comments

Post a Comment

Popular posts from this blog

AlphaFold2 Part 2: The ion channel challenge

Last month I wrote about the wonders and perils of the artificial intelligence program that predicts 3D protein structures, AlphaFold2. As an ion channel enthusiast , I naturally wanted to know how AlphaFold2 performs at predicting the structures of proteins embedded in cell membranes. When I search PubMed for articles that mention both "AlphaFold" and "ion channel" I only get 34 hits. This surprised me, given the hype and the general paranoia around AI replacing humanity. If we use these search results as a proxy for the state of the ion channel protein structure prediction field, I'd say the juice is still in the coconut. I wanted to know how well AF2 would do at predicting an ion channel protein structure, so I asked it to generate the structure of Kv2.1, a voltage-gated potassium ion channel that I studied during graduate school. Kv2.1 is a pretty important protein. It regulates neuron firing throughout the brain and body where it helps us learn new stuff, ...
Post a Comment
Read more

iPSCs, the new model organism?

Induced pluripotent stem cells. The name doesn't exactly roll off the tongue and it certainly doesn't conjure images of mice, fruit flies, monkeys, or any of the other classic model organisms used for basic biomedical research. These so called "model organisms" are just that; animals that help scientists model the way that the most promising human therapeutics in the collective pipeline will behave in humans. And now induced pluripotent stem cells, or iPSCs, are becoming an increasingly popular tool used for developing and testing novel drugs way before we expose any real human patients to them. The upside to using model organisms is pretty obvious -- we minimize exposure of humans to potentially unsafe molecules. The downsides are many, but one big one is that sometimes potential new drug molecules look really promising when they are given to a mouse with a human-like disease, but then that same molecule does nothing (or worse, is toxic!) when it goes into human clin...
Post a Comment
Read more

My take on AlphaFold2

I haven't spent too much time thinking about AlphaFold2 (AF2) since it entered the structural biology zeitgeist, but I was watching Veritasium's recent video on the topic and thought I would learn a bit more about it. For those who haven't heard of AlphaFold2, I highly recommend watching the video linked above, which explains AF2 better than I ever could. But the tl;dr version is this: AlphaFold2 is an artificial intelligence that takes any amino acid sequence (the building blocks of all proteins) as its input, and outputs the 3D protein structure it thinks that sequence is most likely to take. For some sequences, AlphaFold2 can do quite well at this notoriously complex task. On its debut in 2021, it was able to predict the 3D position of atoms in some protein backbones to within a few hundred nanometers! There are a plethora of articles out there speculating about how AF2 is going to change biology and the world at large. But someone recently asked me my opinion: "...
Post a Comment
Read more